Literature DB >> 3353516

Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease.

F Thomas1, J M Cosset, P Cherel, N Renaudy, P Carde, J D Piekarski.   

Abstract

Sequential thoracic CT-scanning was performed for 14 patients presenting with residual mediastinal masses on chest X-ray after treatment of stage I and II Hodgkin's disease (HD). Eleven patients initially presented with bulky mediastinal involvement. No mediastinal biopsy was performed. No local recurrence was detected at a 48 month median follow-up. Early evaluation by CT-scanning showed cystic degeneration in three cases. Sequential CT-scans on longer follow-up demonstrated continuous regression of residual masses in six cases and no or limited volume reduction in six other cases. In two patients, part of the residual mass remained stable and the other part showed reduction in size. In addition, late calcifications developed in four cases. The results of sequential CT-scanning suggest that residual mediastinal masses do not generally represent active disease. Hence additional, potentially toxic, therapy can be avoided.

Entities:  

Mesh:

Year:  1988        PMID: 3353516     DOI: 10.1016/0167-8140(88)90247-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

Review 1.  Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.

Authors:  Karoline Spaepen; Sigrid Stroobants; Gregor Verhoef; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-23       Impact factor: 9.236

Review 2.  Current role of gallium scanning in the management of lymphoma.

Authors:  A F McLaughlin; M A Magee; R Greenough; K C Allman; A E Southee; S R Meikle; B F Hutton; D E Joshua; G J Bautovich; J G Morris
Journal:  Eur J Nucl Med       Date:  1990

3.  [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?

Authors:  Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Guy Bormans; Jan Balzarini; Gregor Verhoef; Luc Mortelmans; Peter Vandenberghe; Christine De Wolf-Peeters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-25       Impact factor: 9.236

4.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.

Authors:  Tatsuo Torizuka; Fumitoshi Nakamura; Toshihiko Kanno; Masami Futatsubashi; Etsuji Yoshikawa; Hiroyuki Okada; Masahide Kobayashi; Yasuomi Ouchi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.